We thank Necchi et al for their letter regarding our recent report. They detail their interesting experience with neoadjuvant pembrolizumab. We would like to respond to the points they raised.
Reply to Andrea Necchi, Antonella Messina, and Alberto Briganti's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol 2018;74:294–306 / Panebianco, V.; Barentsz, J.; Narumi, Y.; Catto, J.. - In: EUROPEAN UROLOGY. - ISSN 0302-2838. - 74:5(2018). [10.1016/j.eururo.2018.06.029]
Reply to Andrea Necchi, Antonella Messina, and Alberto Briganti's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol 2018;74:294–306
Panebianco V.
Primo
;
2018
Abstract
We thank Necchi et al for their letter regarding our recent report. They detail their interesting experience with neoadjuvant pembrolizumab. We would like to respond to the points they raised.| File | Dimensione | Formato | |
|---|---|---|---|
|
Panebianco_Reply-to-bladder-cancer_2018.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
149.62 kB
Formato
Adobe PDF
|
149.62 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
